Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
May 9, 2014
Related Stories
No related posts.
You’re leaving the BioMarin website.
Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.
